MD-7246

MD-7246 is a delayed-release formulation of linaclotide designed to target the ileocaecal junction and caecum with the aim of relieving abdominal pain independently of bowel function. It was developed as an oral, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D)[1][3][7]. The formulation was specifically designed to provide targeted delivery of linaclotide to the colon, where the majority of the abdominal pain associated with IBS is believed to originate, and to limit fluid secretion in the small intestine resulting in minimal impact on bowel function[1][7].

Other names

DR2DR-2DR 2